+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

A

Actively Recruiting

Transthyretin Amyloid Cardiomyopathy ATTR-CM is a serious heart condition caused by the buildup of misfolded transthyretin protein in the heart muscle, leading to heart stiffness and progressive heart failure. There are two types a hereditary form and a wild-type form related to aging. Diagnosing ATTR-CM can be challenging because its symptoms resemble other heart diseases, but advances in medical imaging have improved early detection. Acoramidis is a new medication designed to stabilize the transthyretin protein and prevent harmful buildup. The ACO-REAL study is an observational research project aiming to collect real-world data on acoramidis use in patients with ATTR-CM. This study will observe adults diagnosed with either wild-type or variant ATTR-CM who are starting acoramidis treatment as part of their routine care in approximately 20 European countries. It includes patients new to treatment as well as those who have received other therapies. Researchers will document patient characteristics, how acoramidis is used in everyday clinical practice, and any side effects. The study does not introduce experimental treatments but follows patients receiving acoramidis according to normal medical standards. Participants will be followed for about 12 to 15 months after starting acoramidis. Researchers will collect data on heart function, functional capacity like walking ability, overall health, quality of life, and healthcare usage such as hospital visits. They will also monitor for adverse events during this period. This information aims to improve understanding of ATTR-CM and optimize patient care in real-world settings.

Age: 18Years +All Genders
17 locations
R

Actively Recruiting

Researchers are observing how men with metastatic hormone-sensitive prostate cancer mHSPC respond to treatment with darolutamide combined with androgen deprivation therapy ADT, with or without the chemotherapy drug docetaxel. This international, open-label, multi-cohort study aims to understand the real-world effectiveness and safety of these treatments in routine medical practice. The study will enroll about 1,600 male patients primarily from Europe, focusing on those already decided to receive darolutamide before joining the study. Participants will be divided into two groups one receiving darolutamide plus ADT and docetaxel triplet therapy, and the other receiving darolutamide plus ADT without docetaxel doublet therapy. Treatment is given according to local standard care and chosen by the treating physician. No additional study-specific treatments or procedures are required, as data is collected during routine care visits over the study period. During the study, researchers will collect data on prostate-specific antigen PSA levels, survival rates, time to new treatments, progression of disease, adverse events, quality of life, and other clinical information. Data collection is done via electronic records during regular doctor visits with no extra tests beyond standard care. The study will last up to four years with periodic analyses to help improve understanding of darolutamide use in everyday clinical settings.

Age: 18Years +MALE
16 locations
O

Actively Recruiting

Researchers are observing how the drug aflibercept Eylea is used to treat preterm babies with retinopathy of prematurity ROP in the United Kingdom. ROP is an eye condition affecting premature infants, especially those born before 32 weeks of pregnancy or weighing less than 1.5 kilograms, which can lead to vision problems or blindness. This study aims to determine how many babies receive aflibercept using a paediatric dosing device PDD and to collect data on patient characteristics and disease features. The study collects data only from preterm babies treated with aflibercept 0.4 mg administered via a prefilled syringe PFS combined with a paediatric dosing device PDD. This drug-device combination is approved for treating babies with ROP. Data will be gathered from the National Neonatal Research Database covering babies born from March 2024 to March 2025, or up to April 2027 if more data are needed. No new treatments, visits, or tests are required for study participation since it is observational. Participants existing medical data are reviewed to count how many babies received the treatment and to describe their age, sex, race, and clinical signs. Researchers will analyze outcomes including maternal factors, comorbidities, resource use, and ocular disease information up to three years after the drugs market introduction. The study does not involve active interventions and will monitor data until April 2027, with no additional procedures for participants.

Age: 0 - 1YearAll Genders
1 location
E

Actively Recruiting

Researchers are investigating whether early atrial fibrillation ablation reduces cardiovascular events in patients with atrial fibrillation who have a high burden of other health problems, measured by a CHA2DS2-VASc score of 4 or more. This is an international, randomized, open trial designed to compare early ablation with usual care to see if it lowers risks of stroke, cardiovascular death, or heart failure events. The study also looks at safety, patient-reported outcomes, and cognitive function in this population. Participants are randomly assigned to one of two groups one group undergoes early atrial fibrillation ablation, specifically pulmonary vein isolation within two months of randomization, while the other group receives usual care following guideline-based treatments tailored to their individual medical needs. All treatments involved are approved therapies. The trial aims to enroll 2312 patients and will continue until a set number of cardiovascular events have occurred, with an estimated average follow-up of about four years. During the study, researchers will monitor cardiovascular complications including death, stroke, and hospitalizations related to heart failure. They will also track serious complications from atrial fibrillation therapy and assess quality of life, heart function, rhythm status, cognitive function, and hospital stays over the follow-up period. Patients will be regularly evaluated for both safety and effectiveness outcomes throughout the study duration.

Age: 18Years +All GendersPhase Not Applicable
7 locations